ViaCyte wins $6M to advance stem cell treatment for diabetes

02/15/2013 | Genetic Engineering & Biotechnology News

The California Institute for Regenerative Medicine and JDRF, the type 1 diabetes research advocacy group, have agreed to give $3 million each to support ViaCyte's development of a stem cell treatment for type 1 diabetes. ViaCyte plans a regulatory application to conduct proof-of-concept human trials.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA